3-Bromobenzimidamide hydrochloride

Catalog No.: 
ACTEZJ749
CAS No.: 
16796-52-4
Molecular Formula: 
C7H8BrClN2
Molecular Weight: 
235.51
3-Bromobenzimidamide hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g97%$111.00In stockInquiry
100g97%$388.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-Bromobenzimidamide hydrochloride
IUPAC Name3-bromobenzimidamide hydrochloride
MDL No.MFCD04114439
Molecular FormulaC7H8BrClN2
Molecular Weight235.51
SMILESN=C(N)C1=CC=CC(Br)=C1.[H]Cl
InChI KeyXIZFRYIWRFNILW-UHFFFAOYSA-N
Synonym3-BROMOBENZAMIDINE HCL | Benzenecarboximidamide, 3-bromo-, monohydrochloride | SCHEMBL3764471 | 3-bromobenzenecarboximidamide hydrochloride | EN300-156238 | SY028768 | 3-Bromobenzamidine hydrochloride | 3-bromo-benzamidine hydrochloride | 3-bromobenzimida
CAS No.16796-52-4
PubChem CID12207718

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACTEZJ749 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEMHO382 route compound structure diagram
    ACEMHO3826952-59-6In Stock
  2. Plus
  3. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6In Stock
  4. Then
  5. ACTEZJ749 route product structure diagram
    ACTEZJ74916796-52-4In Stock
Inquiry

2. ACTEZJ749 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTEZJ749 route product structure diagram
    ACTEZJ74916796-52-4In Stock
Inquiry

3. ACTEZJ749 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTEZJ749 route product structure diagram
    ACTEZJ74916796-52-4In Stock
Inquiry

Comments (0)